AstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung cancer with certain mutations, compared with older alt
This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR (Tumour Drivers and Resistance) Patrick Connor explaining why the
For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s the company’s director of oncology advocacy and government affairs, to talk
AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.
